Revuelta-Herrero, J L <br/><br/>
Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.  [electronic resource] 

 -  Journal of clinical pharmacy and therapeutics  Dec 2018 
 - 906-909 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1365-2710 
<br/><br/><label>Standard No.: </label>10.1111/jcpt.12727  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Aged<br/>Anilides--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Antiviral Agents--administration & dosage<br/>Carbamates--administration & dosage<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Lactams, Macrocyclic<br/>Liver Neoplasms--drug therapy<br/>Macrocyclic Compounds--administration & dosage<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Prospective Studies<br/>Ritonavir--administration & dosage<br/>Sorafenib--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Treatment Outcome<br/>Uracil--administration & dosage<br/>Valine